Diabetes Drug Linked To Increased Risk Of Heart Failure Claims New Research

Main Category: Heart Disease
Also Included In: Cardiovascular / Cardiology;  Diabetes
Article Date: 20 Aug 2009 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:3 stars

3 (2 votes)

Healthcare Prof:4 and a half stars

4.2 (5 votes)


New research claims that rosiglitazone, a drug used to treat Type 2 diabetes, is associated with an increased risk of heart failure and death among older people compared to a similar drug called pioglitazone.

Researchers in Canada compared the risk of heart attack, heart failure and death in people treated with rosiglitazone and pioglitazone. They identified nearly 40,000 people aged 66 years and older who started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008.

Confirmation of previous studies

Dr Iain Frame, Director of Research at Diabetes UK, said: "This is a well-designed retrospective study of older people with Type 2 diabetes using rosiglitazone or pioglitazone. Both drugs carry an increased risk of heart failure. The findings confirm previous results of other studies showing that pioglitazone is associated with a reduced risk of heart failure and death but not heart attack compared to rosiglitazone.

"This study adds to the overall body of evidence about the effects of these drugs, yet the claim that one drug is safer than the other remains inconclusive. Perhaps longer term follow-up studies investigating the effectiveness and safety of drugs in clinical practice would be useful.

"The Medicines and Healthcare products Regulatory Authority (MHRA) and the European Medicines Agency state that rosiglitazone is a safe and effective treatment for those diagnosed with Type 2 diabetes. Glitazones are not presently recommended for people who have had, or who are at high risk of having, heart failure or if people are at risk of bone fractures. If you are concerned about taking rosiglitazone, you should contact your GP or healthcare team."

What the drugs do

Rosiglitazone and pioglitazone belong to a class of drugs called thiazolidinediones and help to control blood glucose levels but both drugs can also cause side effects including weight gain, fluid retention and heart failure.

Source
Diabetes UK

Article adapted by Medical News Today from original press release.
Visit our heart disease section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Diabetes UK. "Diabetes Drug Linked To Increased Risk Of Heart Failure Claims New Research." Medical News Today. MediLexicon, Intl., 20 Aug. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/161305.php>

APA
Diabetes UK. (2009, August 20). "Diabetes Drug Linked To Increased Risk Of Heart Failure Claims New Research." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/161305.php.

Please note: If no author information is provided, the source is cited instead.




Heart Disease

What is Atrial Fibrillation?

The human heart has two upper chambers and two lower chambers. The upper chambers are called the left atrium and the right atrium - the plural of atrium is atria. The two lower chambers are the the left ventricle and the right ventricle. Read more...

Most Popular Articles



Follow Our Heart Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Heart Disease Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »